Targeting circulating IgG for the Treatment of Autoimmune Disease
Time: 12:00 pm
day: Post-Conference Focus Day: Next Generation TPD
Introducing the concept of extracellular protein degradation and highlighting its idiosyncrasy and potential advantages over other approaches with the focus on Biohaven Pharmaceuticals’ ASGPR based degradation.
- Uncovering IgG degradation in discovery and preclinical studies – progression of a development candidate towards IND
- Considering what else can be done; Targets, indications, applications